Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07473154

Title field or adapter rule

{'original_value': 'Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA).', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:34.148062+00:00

Published At

2026-10-19T00:00:00+00:00

Record Updated At

2026-10-19

Source Retrieved At

2026-10-31T22:18:41.628690+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Diffuse Cutaneous Systemic Sclerosis", "Rheumatoid Arthritis (RA)", "Systemic Sclerosis (SSc)", "Autoimmune Rheumatologic Disease"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-19", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07473154"

protocolSection.identificationModule.officialTitle

"Phase I/II Study of QEL-005 in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) and in Patients With Difficult to Treat Rheumatoid Arthritis (D2TRA)."

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Diffuse Cutaneous Systemic Sclerosis (protocolSection.conditionsModule.conditions)
• Rheumatoid Arthritis (RA) (protocolSection.conditionsModule.conditions)
• Systemic Sclerosis (SSc) (protocolSection.conditionsModule.conditions)
• Autoimmune Rheumatologic Disease (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Dose Escalation', 'Dose Expansion'], 'description': 'QEL-005 is an autologous cell therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against the B cell marker CD19. Treatment will be given via an IV infusion.', 'name': 'QEL-005', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• QEL-005 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.